CASI Pharmaceuticals Overview
CASI Pharmaceuticals (CASI) has a ROE of 172.7%, above the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow172.70%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CASI is 172.7%. That is above the Healthcare sector average of 20.86%. Investors often review this figure alongside CASI Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CASI currently prints 172.7% for ROE, while the sector average sits near 20.86%. That is roughly 728.0% above the sector mean. Large gaps often invite a closer look at CASI Pharmaceuticals's growth, margins, and balance sheet.
Return on Equity shows how effectively CASI Pharmaceuticals converts resources into returns. At 172.7%, CASI may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CASI's ROE (172.7%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack CASI Pharmaceuticals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
